Dolutegravir‐induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication

Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kiran Dhonju, Ashmita Gautam, Abhinav Dahal, Niraj Kumar Sharma, Divas Adhikari, Lina Devkota, Prabhat Adhikari, Sampurna Tuladhar, Bishnu Deep Pathak, Sabin Banmala
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-12-01
Col·lecció:	Clinical Case Reports
Matèries:	acquired sideroblastic anemia adverse drug reaction Dolutegravir HIV Naranjo scale
Accés en línia:	https://doi.org/10.1002/ccr3.8301
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!